Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04053673|
Recruitment Status : Recruiting
First Posted : August 12, 2019
Last Update Posted : November 24, 2021
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1 interferon) that tells the immune system that something is wrong and to kill the cell. RBN-2397 has been shown in animal studies to inhibit tumor growth and also shuts down the "don't kill me" signal the tumor is sending to evade the immune system. As a PARP7 inhibitor RBN-2397 is different from drugs inhibiting PARP1, PARP2 and PARP3 enzymes which are approved for the treatment of certain ovarian and breast cancers.
The primary purpose of this study is to determine the maximum tolerated dose (MTD) of orally administered RBN-2397 in patients with advanced or metastatic solid tumors. This study will also evaluate the safety and tolerability of RBN-2397, examine the pharmacokinetics (PK) (measure how the body absorbs, breaks down and eliminates RBN-2397) and investigate whether it has antitumor activity in solid tumor cancers.
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumor, Adult||Drug: RBN-2397||Phase 1|
This is a first-in-human, Phase 1, multi-center, open-label, dose-escalation study to:
- Evaluate the safety profile and MTD of RBN-2397 administered orally and establish the RBN-2397 dose(s) and schedule(s) recommended for further investigation in Phase 2
- Characterize the PK profile of RBN-2397
- Identify preliminary antitumor activity.
- Biomarkers and their correlation with response to RBN-2397 and other outcomes will be examined.
Cohorts will follow a traditional 3 + 3 design. After enrollment of the first participant within a cohort, there must be a wait period of at least 1 week before enrollment of additional participants in that cohort. This dose escalation phase of the study is complete.
The study is currently in the Relative Bioavailability and Expansion Cohort(s) phase where approximately 20 participants each will be enrolled to further examine the safety, PK, pharmacodynamics, and antitumor activity of RBN-2397 at the recommended phase 2 dose.
Relative Bioavailability Assessment:
An evaluation of relative bioavailability of a micronized RBN-2397 tablet versus the standard RBN-2397 tablet (manufactured with unmicronized RBN-2397 and used in the dose escalation phase of the study) will be performed as part of the dose escalation phase. Micronized tablets will be used in the Dose Expansion Phase of the study after the relative bioavailability assessment has been completed.
Dose Expansion Phase The recommended phase 2 dose will be investigated in the following cancer types: squamous cell carcinoma of the lung (SCCL), head and neck squamous cell carcinoma (HNSCC), hormone receptor positive (HR+) breast cancer, and PARP7 amplified cancer.
Duration of treatment:
It is anticipated that the minimum study involvement will be one cycle. Participants are eligible to have an indefinite number of additional cycles of treatment if their disease does not progress and they do not have unacceptable side effects.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||130 participants|
|Intervention Model:||Sequential Assignment|
|Intervention Model Description:||Dose Expansion|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors|
|Actual Study Start Date :||August 1, 2019|
|Estimated Primary Completion Date :||December 31, 2022|
|Estimated Study Completion Date :||January 31, 2023|
Dose Escalation: Multiple doses of RBN-2397 for oral administration Dose Expansion: Oral dose of RBN-2397 as determined during Dose Escalation
an oral PARP7 Inhibitor
- Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) [ Time Frame: through first treatment cycle (an average of 21 days) ]Incidence of Dose limiting Toxicities (DLTs)
- Safety and tolerability [ Time Frame: through study completion (an average of one year) ]Grade and frequency of adverse events and serious adverse events
- Area under the plasma concentration for tablet manufactured with micronized RBN-2397 relative to unmicronized RBN-2397 (standard tablet) (Relative Bioavailability Cohorts only) [ Time Frame: Through Study Day 22 ]Area-under-the-curve (AUC inf)
- Peak plasma concentration for tablet manufactured with micronized RBN-2397 relative to unmicronized RBN-2397 (standard tablet) (Relative Bioavailability Cohorts only) [ Time Frame: Through Study Day 22 ]Cmax
- Antitumor activity that may be associated with RBN-2397 treatment assessed by CT/MRI Response Evaluation Criteria for Solid Tumors (RECIST) Criteria v1.1 [ Time Frame: Every 6-8 weeks; through study completion (an average of one year) ]Objective response rate (ORR)
- Antitumor activity that may be associated with RBN-2397 treatment [ Time Frame: Every 6-8 weeks; through study completion (an average of one year) ]Disease control rate (DCR)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04053673
|Contact: Clinical Operations Manageremail@example.com|
|United States, Colorado|
|University of Colorado Anschutz Medical Campus||Recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Aaron Parsons 720-848-4603 firstname.lastname@example.org|
|Principal Investigator: Erin Schenk, MD|
|Denver, Colorado, United States, 80218|
|Contact: Gerald Falchook, MD 281-221-0693 Gerald.Falchook@SarahCannon.com|
|Principal Investigator: Gerald Falchook, MD|
|United States, Connecticut|
|Yale Cancer Center, Yale University||Recruiting|
|New Haven, Connecticut, United States, 06520|
|Contact: Haley Dunning 203-785-4267 Haley.email@example.com|
|Principal Investigator: Patricia LoRusso, DO, PhD|
|United States, Florida|
|SCRI-Sarasota/Florida Cancer Specialists||Recruiting|
|Sarasota, Florida, United States, 34232|
|Contact: Manish Patel, MD 941-377-9993 firstname.lastname@example.org|
|Principal Investigator: Manish Patel, MD|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Shannon Smith 617-643-5965 email@example.com|
|Principal Investigator: Dejan Juric, MD|
|Dana Farber Cancer Institute||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Amanda Fiorentino 617-632-5485 firstname.lastname@example.org|
|Principal Investigator: Geoffrey Shapiro, MD|
|United States, Tennessee|
|Nashville, Tennessee, United States, 37203|
|Contact: Melissa Johnson, MD 615-329-7274 email@example.com|
|Principal Investigator: Melissa L. Johnson, MD|
|United States, Texas|
|MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030-4009|
|Contact: Timothy A Yap, MD, PhD 713-563-1784 firstname.lastname@example.org|
|Principal Investigator: Timothy A Yap, MD, PhD|
|Principal Investigator:||Melissa L Johnson, MD||Tennessee Oncology, PLLC|